Compliance in an Outsource Manufacturing Model: What to Look For - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compliance in an Outsource Manufacturing Model: What to Look For
The authors provide detailed lists of important checkpoints to consider when selecting an outsourcing provider.


Pharmaceutical Technology


Equipment

  • Are all critical support systems (e.g., water for injection, nitrogen, clean compressed air, clean steam, equipment cleaning, vial washing, closure processing) validated?
  • Is each idle piece of equipment clearly marked "needs cleaning" or "cleaned, ready for service"?
  • Is idle equipment stored in a designated area?
  • Are there operational SOPs for instruments?
  • Are written procedures available for each piece of equipment used in the testing or holding of components, in-process material or drugs?
  • Are all pieces of equipment clearly identified with easily visible markings?
  • Are all pieces of equipment also marked with an identification number that corresponds with an entry in an equipment log?
  • Does each piece of equipment have written instructions for maintenance that includes a schedule for maintenance?
  • Is there a maintenance log for each piece of equipment?
  • Are there use logs for all analytical equipment?
  • Are written procedures established for the cleaning and maintenance of equipment and utensils (e.g., autoclave, oven, tanks)?
  • Has a written schedule been established and is it followed for equipment cleaning?
  • Are written records maintained on equipment cleaning, sanitizing, and maintenance on or near each piece of equipment?
  • Does the facility have approved written procedures for checking and calibrating each piece of measurement equipment?
  • Is all instrumentation installed and qualified (installation qualification, operational qualification, and performance qualification, IQ/OQ/PQ) with supporting documentation?
  • Is there a program for qualifying equipment? Have all appropriate pieces of equipment been validated?
  • When computers are used to automate production or quality testing, have the computer and software been validated?

Organized sample storage, material and component control

Laboratory samples

  • Are samples collected and identified properly and according to SOPs?
  • Is the receipt, storage, handling, inventorying and disposing of samples adequately tracked?
  • Is chain-of-custody maintained?
  • Does the laboratory have the facility and controls to ensure proper storage of samples under appropriate conditions (e.g., refrigeration) from the time of receipt to disposition?
  • Is there a procedure for reserve and retention samples?
  • Is this procedure followed?

Laboratory chemicals, solutions, and reagents

  • Are all containers identified?
  • Is there an expiration or retest date on each container based on manufacturer information or stability data?
  • Do standardized volumetric solutions, reagents, and solutions have reference to notebook on preparation?

Standards, testing, and methods

  • Are standard solutions and reagents properly handled?
  • Is there adequate expression and recording of laboratory measurements (e.g., procedures for data rounding and averaging)?
  • Is there proper handling, qualification, and requalification of reference standards?
  • Is there testing and monitoring of process water (e.g., water for injection as well as deionized and USP water)?
  • Is there adequate handling of modifications to analytical methods?
  • Are there procedures for the formalization of analytical methods?
  • Are there procedures for interlaboratory methods transfer and qualification?
  • Are there procedures for resampling, retesting, and rechromatography?


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here